RC
SNOA icon

RegentAtlantic Capital’s Sonoma Pharmaceuticals SNOA Stock Holding History

RegentAtlantic Capital’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-17
Closed -$15K – 388
2016
Q1 		$15K Buy
+17
New +$15.8K ﹤0.01% 378

Other funds holding SNOA

BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MFS
MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return

RegentAtlantic Capital's SNOA Position: Q2 2016 in Review

RegentAtlantic Capital sold out of Sonoma Pharmaceuticals (SNOA) in Q2 2016, closing a stake of 17 shares — an estimated $15K sold.

RegentAtlantic Capital first reported a position in SNOA in Q1 2016 and held it in 1 quarter. The position peaked at $15K in Q1 2016. 14 funds tracked by Wall St. Rank hold SNOA as of Q2 2016.

  • RegentAtlantic Capital reported no remaining Sonoma Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • RegentAtlantic Capital sold 17 Sonoma Pharmaceuticals shares in Q2 2016, an estimated $15K.
  • RegentAtlantic Capital first reported a position in Sonoma Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • RegentAtlantic Capital's Sonoma Pharmaceuticals position peaked at $15K in Q1 2016.
  • 14 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2016.

Based on RegentAtlantic Capital's 13F filing for Q2 2016, filed 18 Jul 2016.